PDCD1 and colorectal carcinoma: Although no objective responder to pembrolizumab is seen in pMMR/MSS‐CRC, some patients obtained SD lasting more than 3 months according to tumor markers as well as radiographical evaluation,55 indicating that some groups of MSS‐CRC could respond to PD‐1 blockade.